Poultry Vaccines Global Market Report 2024

The poultry vaccines market size has grown strongly in recent years. It will grow from $1.64 billion in 2023 to $1.8 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The growth observed in the historic period can be attributed to several factors, including epidemic outbreaks affecting the poultry industry, the globalization of poultry trade, shifts in consumer demand for poultry products, heightened environmental concerns, the emergence of infectious diseases impacting poultry, and a growing focus on alternatives to antibiotics in poultry farming.

The poultry vaccines market size is expected to see strong growth in the next few years. It will grow to $2.59 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The anticipated growth in the forecast period can be attributed to various factors, including disease mutation and evolution, the global expansion of the poultry industry, a heightened demand for protein-rich foods, increasing environmental concerns and a focus on sustainability, as well as a rising emphasis on animal welfare. Major trends expected in this period include the digitalization of vaccination management, a shift towards antibiotic alternatives, advancements in production efficiency, the emergence of infectious diseases, and an increased focus on environmental considerations.

The growth in the poultry vaccine market is expected to be propelled by the increasing prevalence of zoonotic diseases. Zoonotic diseases, caused by pathogenic agents such as viruses, bacteria, parasites, and fungi, are diseases that can be transmitted between animals and humans. Factors such as changes in land use, heightened urbanization, and climate change have been linked to the onset of zoonotic diseases, increasing the risk of transmission. The surge in zoonotic cases has led to a growing demand for poultry vaccines. For instance, a July 2022 article published by the World Health Organization reported a 64% increase in zoonotic cases in Africa. The rise in zoonotic illnesses globally and in India underscores the need for effective prevention measures, with emerging infectious diseases in humans accounting for a significant portion of cases. This increased risk is expected to drive the demand for poultry vaccines.

The growth of the poultry vaccine market is anticipated to be fueled by the increasing consumption of meat. Meat, as a primary source of protein in many diets, is derived from the flesh of animals and is a key component of human nutrition. Poultry vaccines play a crucial role in ensuring the safety and quality of meat products by protecting against infectious diseases in poultry. Consumers are more likely to trust and choose meat from poultry that has been vaccinated, as it reduces the risk of foodborne illnesses and contributes to increased productivity in poultry farming. For example, according to Chilecarne, a Chile-based association representing meat-exporting companies, the global meat supply is projected to reach 374 million tons by 2030. The rising meat consumption worldwide is thus expected to drive the growth of the poultry vaccines market.

Technological advancements in poultry vaccines represent a significant trend gaining traction in the poultry vaccines market. The integration of innovative technologies has led to vaccines becoming highly effective and cost-efficient tools for preventing illnesses in poultry animals. Key players in the poultry vaccine market are actively engaged in the development of new technological solutions to enhance their market positions. For example, in October 2023, Zoetis Inc., a leading US-based animal health company, introduced Circomax, a porcine circovirus type 2 (PCV2) vaccine designed to address multiple genotypes (a, b). This vaccination aims to provide comprehensive protection against various PCV2 risks, including the three genotypes observed in the UK pig herd. Circomax is the only PCV2 vaccine licensed to safeguard against all three genotypes, demonstrating efficacy, convenience, and proven safety in protecting piglets from PCV2a, PCV2b, and PCV2d.

Major companies in the poultry vaccines market are forging strategic partnerships to foster product development and enhance their market positions. Collaborative efforts and partnerships in this sector promote innovation, leverage complementary expertise, and expedite the development and commercialization of advanced therapies. In October 2023, Kemin Industries Inc., a prominent US-based ingredient manufacturer dedicated to improving the quality of life for people and animals, joined forces with Ilender Corporation, a pharmaceutical company based in Peru, to launch the mefluvac H5 plus 8 vaccine. This vaccine aims to provide protection against avian influenza risks, specifically targeting the H5N1 and H5N8 subtypes. The vaccine, designed as an emulsified, trivalent, inactivated water-in-oil (W/O) virus for immunizing hens, offers a crucial defense against evolving threats by closely resembling local strains. The introduction of MEFLUVAC H5 PLUS 8 marks a significant milestone for Kemin Biologics' expansion in the Latin American market, contributing to the advancement of the Peruvian poultry sector by delivering robust, long-lasting protection for healthy birds.

In August 2022, Bimeda, an Ireland-based developer, manufacturer, and marketer of veterinary pharmaceuticals and animal care products, completed the acquisition of Afrivet for an undisclosed amount. This strategic move positions Bimeda as having the most extensive footprint among animal health companies in Africa. Afrivet, a South Africa-based manufacturer of poultry vaccines, contributes to Bimeda's commitment to serving the African continent's diverse animal health needs.

Major companies operating in the poultry vaccines market report are Merck & Co. Inc., Boehringer Ingelheim International GmbH, Zoetis Inc., Ringpu Biology, MSD Animal Health, Elanco Animal Health Incorporated, Ceva Santé Animale S.A., Phibro Animal Health Corporation, Huvepharma AD, Venkys India Limited, Vetoquinol S.A., Indian Immunologicals Limited, Vaccination Services Pvt. Ltd., Indovax Private Limited, Pharmaq AS, Bio-Vet Inc., Hester Biosciences Limited, Intervet Inc., Anicon Labor GmbH, CZ Veterinaria S.A., Bioproperties Pty Ltd., Torigen Pharmaceuticals Inc., Bioveta a.s., Aptimmune Biologics Inc., HIPRA S.A., Biovac (Pty) Ltd., VerovacciNES Inc., Lohmann Animal Health GmbH & Co. KG, Nisseiken Co. Ltd., Zydus Animal Health Limited, Jinyu Bio-Technology Co. Ltd., Kyoto Biken Laboratories Inc., Phage Technology Inc.

North America was the largest region in the poultry vaccines market in 2023. The regions covered in the poultry vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the poultry vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Poultry vaccines come in various types, including porcine vaccines, poultry vaccines, livestock vaccines, companion animal vaccines, aquaculture vaccines, and others. Porcine vaccines, a subset of poultry vaccines, involve the use of a high-pressure injector for immunizing pigs. This injector disperses 0.1 to 0.5 milliliters of the vaccination dosage. Porcine vaccines are applied to combat different diseases such as avian influenza and infectious bronchitis, requiring various dosage forms such as liquid vaccines, freeze-dried vaccines, and duct vaccines. Technologies involved in poultry vaccines encompass toxoid, live attenuated vaccines, recombinant vaccines, and inactivated vaccines, which are applied in broiler, layer, and breeder poultry.

The poultry vaccines market research report is one of a series of new reports that provides poultry vaccines market statistics, including poultry vaccines industry global market size, regional shares, competitors with a poultry vaccines market share, detailed poultry vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the poultry vaccines industry. This poultry vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The poultry vaccine market consists of revenues earned by entities by providing poultry vaccine services such as poultry health management, vaccination to poultry ducks, vaccination knowledge management, trainings. The market value includes the value of related goods sold by the service provider or included within the service offering. The poultry vaccine market also includes sales of chicken farm equipment, vaccination syringe, drugs, needle gun which are used in providing poultry vaccine services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.